bharat biotech - Modern Business India

bharat biotech: Bharat Biotech’s Covid-19 nasal vaccine phase III trials completed

Bharat Biotech’s Covid-19 nasal vaccine phase III trials completed | India News

Covaxin safe for 2-18 age group: BB study | India News

lancet: Covaxin safe for kids aged 2-18, found as effective as in adults: Lancet

Covaxin safe, immunogenic in children aged 2-18 years: Lancet | India News

Reduce the gap for Covid booster dose to 6 months: NTAGI | India News

Covid Booster Dose: Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study

omicron: Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study | India News